FindTrial
Sign In

The guiding role of circulating tumor DNA detection technology on TACE treatment and guiding prognosis in hepatocellular carcinoma radical resection

The guiding role of circulating tumor DNA detection technology on TACE treatment and guiding prognosis in hepatocellular carcinoma radical resection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016267
Enrollment
Unknown
Registered
2018-05-22
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

TACE treatment group:TACE
Control:No

Sponsors

Shandong Provincial Qianfoshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: According to the clinical diagnostic standard of primary liver cancer diagnosis standard, patients with radical resection combined with postoperative pathology confirmed hepatocellular carcinoma at the same time, an important function of heart and lung and other organs can be tolerated treatment, the patients with complete clinical and pathological data, no other special anticancer therapy, no other history of cancer.

Exclusion criteria

Exclusion criteria: Pathology confirmed that patients with non hepatocellular carcinoma; severe heart, liver, lung, brain, kidney and other organ complications; due to various reasons lost.

Design outcomes

Primary

MeasureTime frame
disease free survival;—

Countries

China

Contacts

Public ContactJie Li

Shandong Provincial Qianfoshan Hospital

lijie0503@126.com+86 0531-89269815

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026